Korean J Urol.  2011 Nov;52(11):757-762.

Association of Metabolic Syndrome and Benign Prostate Enlargement in Young Korean Males

• Jeong JH
• Kim ET
• Kim DK

Abstract

PURPOSE
This study was designed to evaluate the association of metabolic syndrome and benign prostate enlargement in young Korean males. We analyzed the clinical data associated with metabolic syndrome and prostate volume in the study population.
MATERIALS AND METHODS
We retrospectively analyzed the clinical data obtained from 1,506 young men under the age of 60 who visited the health promotion center in our institution for routine checkups. The patients were interviewed with a questionnaire including the International Prostate Symptom Score (IPSS) and were evaluated by medical history, blood chemistry, digital rectal examination, and prostate volume via transrectal ultrasonography. The presence of metabolic syndrome was determined according to the modified National Cholesterol Education Program Expert Panel on Detection, Evalution, And Treatment of High Blood Cholesterol in Adults criteria. We divided the subjects into two groups: those with metabolic syndrome and those without. Logistic regression analysis was carried out to determine which metabolic components were associated with an increased risk of benign prostate enlargement.
RESULTS
Significant differences in prostate volume were noted between the groups. The prostate volumes were significantly larger in the metabolic syndrome group than in the non-metabolic syndrome group in all subgroups divided by age (in decades). However, no significant differences in IPSS or voiding or storage subscore were noted. In the multivariate regression analysis, only diabetes and obesity were identified as risk factors for benign prostate enlargement among the metabolic components.
CONCLUSIONS
Metabolic syndrome and prostate volume were significantly related, even in young males. Diabetes and obesity were identified as significant risk factors for benign prostate enlargement in young males under the age of 60.

Keyword

Metabolic syndrome X; Prostatic hyperplasia

MeSH Terms

Adult
Cholesterol
Digital Rectal Examination
Health Promotion
Humans
Logistic Models
Male
Metabolic Syndrome X
Obesity
Prostate
Prostatic Hyperplasia
Retrospective Studies
Risk Factors
Cholesterol

Figure

• 

  FIG. 1 Comparison of prostate volume between the metabolic syndrome group and the non-metabolic syndrome group. MS: metabolic syndrome group, Statistical analysis by Student's t-test.

Reference

1. Park YH, Chung MK. The prevalence of clinical benign prostatic hyperplasia and lower urinary tract symptoms in South-East Korea: a community-based study. J Pusan Natl Univ Hosp. 2001. 9:141–157.

2. Lee MW, Lee KS. The prevalence of benign prostatic hyperglasia in self-referral populations over age 50. Korean J Urol. 1996. 37:263–267.

3. Krotkiewski M. Role of muscle morphology in the development of insulin resistance and metabolic syndrome. Presse Med. 1994. 23:1393–1399.

4. Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl. 1996. 17:2–4.

5. Kasturi S, Russell S, Mcvary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep. 2006. 7:288–292.

6. Sohn JC, Chang HS, Kim CI. The correlation between metabolic syndrome and the prostate volume. Korean J Urol. 2007. 48:603–607.

7. Koo KC, Cho KS, Kang EM, Kwon SW, Hong SJ. The relationship between metabolic syndrome and prostate volume in men over sixties who underwent prostate health check-up. Korean J Urol. 2008. 49:813–817.

8. Park JS, Park JK. The meaning of metabolic syndrome X in patients suffering with benign prostatic hyperplasia. Korean J Urol. 2007. 48:696–700.

9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.

10. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993. 44:121–131.

11. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J. 1994. 15:Suppl C. 78–81.

12. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998. 1:157–162.

13. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002. 168:599–604.

14. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007. 51:199–203.

15. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006. 91:2562–2568.

16. Yim SJ, Cho YS, Joo KJ. Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age. Korean J Urol. 2011. 52:390–395.

17. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990. 113:909–915.

18. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.

19. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986. 61:1081–1090.

20. Shieh SM, Sheu WH, Shen DC, Fuh MM, Chen YD, Reaven GM. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens. 1992. 5:827–831.

21. Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, et al. Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate. 2000. 42:45–55.

22. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994. 140:989–1002.

23. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood press. 1999. 8:29–36.

24. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007. 177:1395–1400.

25. Kim JM, Song PH, Kim HT, Moon KH. Effect of obesity on prostate-specific antigen, prostate volume, and International Prostate Symptom Score in patients with benign prostatic hyperplasia. Korean J Urol. 2011. 52:401–405.

26. Kim GW, Doo SW, Yang WJ, Song YS. Effects of obesity on prostate volume and lower urinary tract symptoms in Korean men. Korean J Urol. 2010. 51:344–347.

27. Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Kim YJ, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring). 2006. 14:172–179.